

## Curis to Participate in Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 2, 2015 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will participate at the following upcoming conferences:

**FBR Second Annual Healthcare Conference.** Company management will participate in one-on-one investor meetings throughout the day on September 9, 2015, at the conference venue in Boston.

**Baird 2015 Healthcare Conference.** Dr. Ali Fattaey, President and Chief Executive Officer, will present on September 10, 2015, at 1:25 p.m. Eastern Time in New York City. The company also will conduct one-on-one meetings with investors throughout the day. A corresponding live webcast of the presentation can be accessed by visiting:

<http://wsw.com/webcast/baird43/cris>

The webcast will be archived shortly after the live event and available for 30 days following the conference, and also available for 30 days on the Investor Relations section of the Curis website at [www.curis.com](http://www.curis.com).

### About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907, a dual HDAC and PI3K inhibitor that is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Senior Vice President, Corporate Strategy and

Investor Relations

Curis, Inc.

617-503-6605

[mmohindru@curis.com](mailto:mmohindru@curis.com)

Media Contact

David Schull

Russo Partners

(212) 845-4271

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

---

<https://investors.curis.com/Curis-to-Participate-in-Upcoming-Investor-Conferences>